Dr. Angeli Achrekar
Acting U.S. Global AIDS Coordinator and Special Representative for Global Health Diplomacy
The United States President's Emergency Plan for AIDS Relief
U.S. Department of State
SA-22, Room 10300
Washington, DC 20522-2210

Dear Dr. Achrekar,

We are encouraged by the World Health Organization's recent publication of updated global guidelines for screening and treatment of pre-cancer lesions for cervical cancer prevention. These guidelines provide a clear mandate and scientific rationale for wide-scale adoption of human papilloma virus (HPV) testing as the recommended screening method for women worldwide, including women living with HIV, in lieu of cytology or visual inspection with acetic acid (VIA) screening. The guidelines specifically state:

Existing programmes with quality-assured cytology as the primary screening test should be continued until HPV DNA testing is operational; existing programmes using VIA as the primary screening test should transition rapidly because of the inherent challenges with quality assurance.

As you know, ensuring that 70% of all women receive screening for cervical cancer at ages 35 and 45 is a key pillar of the WHO's strategy to accelerate the global elimination of cervical cancer. Rapid global uptake of HPV testing will facilitate the achievement of this target through more accurate diagnosis and improved prioritization of cervical cancer treatment resources.

Our coalition of advocates for the global elimination of cervical cancer gratefully acknowledges the role played by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) as supporters of the global elimination strategy and WHO's cervical cancer guideline development working group. We recognize that PEPFAR and the Go Further program partners are committed to reducing cervical cancer deaths by 95% in its program countries. We acknowledge the significant achievements of the program to date in increasing access to cervical cancer screening and preventive treatment for women living with HIV in high-burden countries.

Given the clear mandate to move to HPV testing for cervical cancer screening, we would like to understand your process and timeline for moving all PEPFAR cervical cancer screening to HPV testing. Committing to the broader use of HPV testing within PEPFAR programs demonstrates a clear commitment to quality of care for women living with HIV.

The world has made clear its dedication to end cervical cancer everywhere. Bolstered by your leadership, together we can transform the ambition of cervical cancer elimination into reality. We know how to eliminate cervical cancer. It is now a matter of when this goal will be achieved.

Thank you again for your leadership and your commitment.

- 1. TogetHER for Health
- 2. AVAC
- 3. American Cancer Society
- 4. FHI 360
- 5. Global Communities
- 6. Jhpiego
- 7. PATH
- 8. Pathfinder International
- 9. Population Services International
- 10. Advocates for Youth
- 11. AIDS Action Baltimore
- 12. American Medical Women's Association
- 13. BIO Ventures for Global Health

- 14. Cervical Cancer Action for Elimination
- Cervical Cancer Prevention and Training Centre in Catholic Hospital, Battor
- 16. Conquering Cancer
- 17. Elizabeth Glaser Pediatric AIDS Foundation
- 18. ENGAGe Teens
- 19. EngenderHealth
- 20. ESGO Prevention Committee
- 21. Global Focus on Cancer
- 22. Global Initiative Against HPV and Cervical Cancer (GIAHC)
- 23. Go Doc Go
- 24. Grounds for Health
- 25. Haiti sans Cervical Cancer

- 26. Housing Works
- 27. IAVI
- 28. Innovating Health International
- 29. International Association of Providers of AIDS Care
- 30. John Snow International
- 31. KILELE Health Association
- 32. Kizazi Chetu
- 33. Management Sciences for Health
- 34. MSI Reproductive Choices
- 35. Scope
- 36. Treatment Action Group
- 37. VCS Foundation
- 38. International Taskforce on Cervical Cancer Elimination in the Commonwealth







































































CC: Xavier Becerra, Secretary of Health and Human Services
Frances Collins, Director of the National Institutes of Health
Rochelle Walensky, Director of the Centers for Disease Control and Prevention
Jennifer Adams, Senior Deputy Assistant Administrator, U.S. Agency for International Development (USAID)
Bureau for Global Health